Semaglutide compared with peptides: separating fact from confusion

Free consultation included (a GPhC-registered Independent Prescriber reads your answers the same day, not a bot
Once approved, treatment is dispatched the same day for orders placed before 12pm Monday to Friday
Free next-working-day tracked delivery by DPD, in plain unbranded packaging
Priority aftercare seven days a week) no subscriptions, no hidden fees, every repeat clinically re-reviewed

Semaglutide is a peptide — that is the fact most comparisons skip. The real question people are asking is how licensed semaglutide medicines like Wegovy differ from the unlicensed "peptide" products sold online, often marketed as research chemicals or aesthetic treatments. Those are two very different things, and the distinction matters for your safety. Semaglutide belongs to the GLP-1 receptor agonist class, a family of medicines that reduce appetite by mimicking a gut hormone involved in blood-sugar regulation and satiety. In the UK, Wegovy (semaglutide 2.4mg) is a Prescription-Only Medicine, licensed by the MHRA for weight management in eligible adults, reviewed and dispensed only after a clinical assessment by a registered prescriber.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What the evidence actually says — and what the online peptide market doesn't tell you

The misconception worth clearing up first: semaglutide isn't a rival to peptides, it's one of them

There is a persistent idea floating around fitness communities that semaglutide and "peptides" are two separate categories, as if one were a pharmaceutical and the other something more natural. It's an understandable confusion, and worth letting go of gently, because it shapes every decision that follows.

Peptides are simply chains of amino acids. Semaglutide is a synthetic peptide, engineered to mimic GLP-1, a hormone your gut releases after eating. The unlicensed products sold as "peptides" for weight loss (typically via online stores, gym connections or social media) are often also described as GLP-1 mimetics or growth hormone secretagogues. What separates semaglutide peptide from Ozempic and from unregulated alternatives is not chemistry in principle; it is evidence, regulation, manufacturing standards and legal status. Wegovy has been through rigorous clinical trials, assessed by the MHRA, and is manufactured under pharmaceutical-grade conditions. The unlicensed alternatives have not.

The MHRA has warned explicitly about unregulated peptide products and counterfeit weight-loss injectables circulating in the UK, some of which have caused hospitalisations. If you are weighing up your options, that context belongs at the top of the comparison, not the footnote.

How licensed semaglutide (Wegovy) performs in clinical evidence, and what unlicensed peptides cannot show

Wegovy's weight-loss evidence comes from the STEP programme, a series of large clinical trials. In STEP 1, published in the New England Journal of Medicine, adults with obesity using 2.4mg semaglutide weekly alongside lifestyle changes lost an average of around 15% of body weight over 68 weeks, compared with roughly 2.4% on placebo. That is a meaningful difference, achieved with a known safety profile and a licensed dose.

The newer 7.2mg single-dose Wegovy pen, approved by the MHRA in April 2026, has reported average reductions of around 20.7% in trials, narrowing the gap with tirzepatide. You can read more about the relationship between different semaglutide formulations if you want to understand how the dose ladder works.

Unlicensed peptide products sold online carry no equivalent evidence base. Manufacturers cannot legally conduct human weight-loss trials with unregulated compounds in the UK and present them as medical evidence. What circulates instead is anecdote, forum data and marketing copy, none of which a regulator or prescriber can assess for your individual safety.

Semaglutide versus other licensed GLP-1 medicines: a factual comparison

If your question is really about how semaglutide compares with other licensed weight-loss medicines, the picture is clearer. Below is a factual summary, drawn from NICE appraisals and published trial data.

MedicineTypeUK weight-loss licenceAverage weight loss in trialsSource
Semaglutide 2.4mg (Wegovy injection)GLP-1 receptor agonist (peptide)Yes (MHRA/NICE TA875~15% over 68 weeksSTEP 1, NEJM
Semaglutide 25mg (Wegovy tablet)GLP-1 receptor agonist (peptide)Yes) MHRA approved June 2026~13.6% average; ~17% in fully adherent participants over 64 weeksOASIS 4; Novo Nordisk UK
Tirzepatide (Mounjaro)Dual GIP/GLP-1 agonist (peptide)Yes (MHRA/NICE TA1026~20–22.5% at 15mg over 72 weeksSURMOUNT-1, NEJM
Liraglutide (Saxenda)GLP-1 receptor agonist (peptide)Yes) MHRA licensedLower than semaglutide in head-to-head dataNICE/published trials
Ozempic (semaglutide 0.5–2mg)GLP-1 receptor agonist (peptide)No (licensed for type 2 diabetes onlyNot applicable for weight-loss licenceMHRA
Unlicensed "peptide" injectablesVarious (unverified)No) not assessed by MHRANo MHRA-assessed trial dataN/A

Notice that every licensed option in that table is itself a peptide. The comparison people are really making is between regulated and unregulated medicine, not between peptides and something else. For more on how semaglutide sits alongside liraglutide specifically, that comparison is covered separately. And if you want to understand how Ozempic fits (or rather, does not fit) into weight management, our Ozempic and semaglutide page covers the licensing distinction in full.

Getting licensed semaglutide safely in the UK

Wegovy is a Prescription-Only Medicine. The only legal route to it is a prescription following a clinical assessment, there is no shortcut through an online shop or a gym supplier. Any site offering it without that step is operating outside the law, and the MHRA has confirmed that products seized in UK enforcement operations have in some cases contained substances that were actively dangerous.

At nume, our clinical team reviews every consultation the same day it is submitted. A real prescriber (GPhC-registered) reads your medical information and makes the suitability decision. If approved, your treatment ships the same day for orders before 12pm, arriving free the next working day via DPD. To see the full range of licensed treatment options, including Wegovy and Mounjaro, visit our weight-loss treatments page. If you have more general questions about what a private prescription involves, our FAQs answer the ones we hear most often. You can also read more about how to get Wegovy online through a regulated UK pharmacy before you start. Which medicine is right for you is a clinical decision; our prescribers work through it with you, not for you.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions